Russell Investments Group’s Aquestive Therapeutics AQST Stock Holding History

Russell Investments Group’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Buy	260,481 +34,318	+15%	+$144K	﹤0.01%	2426
2026 Q1	$939K	Buy	226,163 +16,733	+8%	+$67.9K	﹤0.01%	2248
2025 Q4	$1.35M	Buy	209,430 +46,045	+28%	+$287K	﹤0.01%	2063
2025 Q3	$913K	Buy	163,385 +35,681	+28%	+$154K	﹤0.01%	2238
2025 Q2	$423K	Buy	127,704 +2,207	+2%	+$6.33K	﹤0.01%	2399
2025 Q1	$364K	Buy	125,497 +16,984	+16%	+$51.4K	﹤0.01%	2405
2024 Q4	$386K	Buy	108,513 +40,626	+60%	+$187K	﹤0.01%	2365
2024 Q3	$338K	Buy	+67,887	New	+$264K	﹤0.01%	2377
2019 Q4	–	Sell	-14,625	Closed	-$46K	–	3081
2019 Q3	$46K	Buy	+14,625	New	+$54.8K	﹤0.01%	2933

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Russell Investments Group's AQST Position: Q2 2026 in Review

Russell Investments Group increased its Aquestive Therapeutics (AQST) stake by 15% in Q2 2026, buying an estimated $144K and bringing the position to 260,481 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2426.

Russell Investments Group first reported a position in AQST in Q3 2019 and has held it in 9 quarters since. The position peaked at $1.35M in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Russell Investments Group held 260,481 shares of Aquestive Therapeutics worth $1.08M as of Q2 2026.
Russell Investments Group bought 34,318 Aquestive Therapeutics shares in Q2 2026, an estimated $144K.
Aquestive Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2426 holding.
Russell Investments Group first reported a position in Aquestive Therapeutics in Q3 2019 and has held it in 9 quarters since.
Russell Investments Group's Aquestive Therapeutics position peaked at $1.35M in Q4 2025.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.